Catherine A Dowling
Overview
Explore the profile of Catherine A Dowling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
185
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montgomery T, Wang Q, Mirza A, Dwyer D, Wu Q, Dowling C, et al.
Sci Rep
. 2024 Jul;
14(1):15292.
PMID: 38961134
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Clinical presentation and disease course are highly...
2.
Montgomery T, Wang Q, Mirza A, Dwyer D, Wu Q, Dowling C, et al.
medRxiv
. 2023 Jul;
PMID: 37425956
Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Clinical presentation and disease course are...
3.
Wu Q, Wang Q, Yang J, Mills E, Chilukuri P, Saad A, et al.
Mult Scler Relat Disord
. 2023 May;
75:104719.
PMID: 37172367
Background: Teriflunomide (TER) (Aubagio™) is an FDA-approved disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS). The mechanism of action of TER is thought to be related to the inhibition of...
4.
Wu Q, Wang Q, Yang J, Martens J, Mills E, Saad A, et al.
J Cent Nerv Syst Dis
. 2021 Nov;
13:11795735211050712.
PMID: 34720605
Background: The long-term prognosis of relapsing-remitting multiple sclerosis (RRMS) is usually unfavorable as most patients transition to secondary progressive multiple sclerosis (SPMS) with accumulative disability. A rare form of non-progressive...
5.
Ali A, Dwyer D, Wu Q, Wang Q, Dowling C, Fox D, et al.
Vaccine
. 2021 Sep;
39(41):6111-6116.
PMID: 34483021
Little is known about COVID-19 mRNA vaccine humoral immune responses in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell...
6.
Wu Q, Mills E, Wang Q, Dowling C, Fisher C, Kirch B, et al.
JCI Insight
. 2020 Jan;
5(3).
PMID: 31935197
BACKGROUNDSiponimod (BAF312) is a selective sphingosine-1-phosphate receptor 1 and 5 (S1PR1, S1PR5) modulator recently approved for active secondary progressive multiple sclerosis (SPMS). The immunomodulatory effects of siponimod in SPMS have...
7.
Wu Q, Wang Q, Mao G, Dowling C, Lundy S, Mao-Draayer Y
J Immunol
. 2017 Mar;
198(8):3069-3080.
PMID: 28258191
Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-remitting multiple sclerosis. To better...
8.
Lundy S, Wu Q, Wang Q, Dowling C, Taitano S, Mao G, et al.
Neurol Neuroimmunol Neuroinflamm
. 2016 Mar;
3(2):e211.
PMID: 27006972
Objective: To test the hypothesis that dimethyl fumarate (Tecfidera, BG-12) affects B-cell subsets in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Peripheral blood B cells were compared for surface marker...